Direct answer
Read the report in layers, not by color alone.
Start with the gene and reported metabolizer phenotype, then find the medication-specific evidence and clinical note. Treat any color, bin, or “use as directed” label as the laboratory's summary—not as a guarantee, prohibition, or medication order.
Pharmacogenomic testing is sometimes marketed as a way to find the “right” antidepressant. That claim is too broad. For selected medications, inherited variation in enzymes such as CYP2D6, CYP2C19, or CYP2B6 may affect drug metabolism or exposure. Response can still be shaped by diagnosis, other medicines, adherence, medical conditions, age, symptoms, prior response, and many factors a panel does not measure.
Synthetic sample—not a patient report
Decode each line before discussing what it means clinically.
| Synthetic report layer | Example wording | What it does—and does not—mean | Question for the prescriber |
|---|---|---|---|
| Gene result | “CYP2C19 variants detected” | Identifies inherited variants tested by that laboratory. It is not a depression diagnosis or a treatment choice. | Which tested gene-drug pairs are relevant to my current options? |
| Predicted phenotype | “Rapid metabolizer” | Translates a genotype into a predicted enzyme-activity category. The consequence differs by medication and evidence. | Is this phenotype supported for this exact medication? |
| Gene-drug note | “Exposure may differ from typical metabolism” | Describes a possible pharmacokinetic effect. It does not by itself prove benefit, harm, or the correct dose for one person. | Does FDA labeling or CPIC guidance address this pair? |
| Vendor category | “Use as directed,” “moderate interaction,” or a color bucket | Summarizes the laboratory's interpretation. Categories and included evidence can differ between reports. | What evidence and non-genetic factors sit behind this label? |
| Clinical decision | Prescriber integrates the result with the full history | This is where diagnosis, prior response, interactions, safety, preference, access, and monitoring belong. | Would this result actually change the plan, and how? |
Evidence hierarchy
FDA, CPIC, and commercial reports answer different questions.
FDA labeling and association table
The FDA table organizes gene-drug relationships by the evidence reviewed. Inclusion does not automatically mean testing is recommended before prescribing. The FDA also says most listed associations have not been evaluated for improved clinical outcomes and that genotype is only one factor.
CPIC guidance
CPIC asks a narrower question: if a genotype result is already available, how might it inform prescribing for supported gene-drug pairs? The current serotonin-reuptake-inhibitor guideline provides recommendations for selected metabolic genes and does not support using every tested gene to guide treatment.
Vendor interpretation
A laboratory may combine multiple sources, tested variants, and proprietary rules into a branded category. Ask for the evidence behind the exact medication annotation instead of assuming one vendor's bucket is a universal standard.
What the trial evidence shows
Testing may improve drug-gene matching without guaranteeing remission.
In the PRIME Care randomized trial, access to pharmacogenomic results reduced prescriptions with predicted drug-gene interactions. The average remission advantage was small and was not persistent at 24 weeks.
That distinction matters when reading marketing claims. A tool can improve one part of medication selection without becoming a test that reliably predicts who will recover. Ask what outcome a claim actually measured, how large the difference was, and whether it lasted.
Bring a focused checklist
Questions that turn a report into a safer conversation
- Which gene-drug pairs on this report apply to medications I use or may discuss?
- Is the note based on FDA labeling, CPIC guidance, another guideline, or the laboratory's own interpretation?
- Does the result concern metabolism, exposure, dosing, side effects, response, or only a theoretical association?
- Which medications, supplements, smoking changes, kidney or liver factors, age, or other conditions could matter more than the genotype?
- Would the result change the plan today? If not, why not?
- What benefit and adverse effects will we measure, and when will we reassess?
- Who should receive a copy of the report, and how should genetic data be stored?
Keep page ownership clear
Use the right guide for the decision in front of you.
Common questions
Antidepressant pharmacogenomic testing questions
What can genetic testing for antidepressants tell you?
For selected gene-drug pairs, a pharmacogenomic result may help a prescriber understand how inherited differences could affect drug metabolism, exposure, or a dosing discussion. It cannot diagnose depression, measure every reason a medicine may help or cause side effects, or identify one antidepressant that is guaranteed to work.
What do green, yellow, or red GeneSight test results mean?
Color or bucket labels are vendor-defined interpretations, not universal clinical outcomes. A green category does not mean a medicine will work, and a yellow or red category does not mean it will fail or must never be used. Read the gene, phenotype, medication-specific note, evidence source, and clinical context behind the category with a qualified prescriber.
Does a pharmacogenomic report choose the best antidepressant?
No. A report addresses only part of a medication decision. Diagnosis, prior benefit and side effects, other medicines, medical conditions, age, pregnancy considerations, symptoms, urgency, preference, cost, and monitoring still matter.
Are FDA, CPIC, and vendor report categories the same thing?
No. FDA-approved labeling and the FDA association table describe regulatory evidence for particular gene-drug relationships. CPIC publishes peer-reviewed guidance for how available genetic results may inform prescribing. A commercial laboratory may combine evidence and its own rules into branded categories. Those layers should not be treated as interchangeable.
Should I stop or change an antidepressant because of a test result?
No. Do not stop, skip, combine, switch, or change a dose based on a webpage or a report category. Abrupt changes can cause withdrawal effects, symptom return, interactions, or other harm. Review the complete report with the prescriber responsible for the medication plan.
Does pharmacogenomic testing improve depression outcomes?
Evidence is mixed and the average benefit is limited. In PRIME Care, testing reduced prescriptions with predicted drug-gene interactions, while the remission advantage was small and not persistent at the end of the 24-week trial. That supports using results as one decision input, not a promise of response.
Authoritative sources
Review the evidence directly
- FDA: Table of Pharmacogenetic Associations
- FDA: Direct-to-Consumer Tests
- CPIC: Serotonin reuptake inhibitor antidepressants and CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A
- PRIME Care randomized clinical trial
This page explains report structure and evidence limits. It does not endorse a test brand or laboratory and cannot interpret a personal result or recommend a medication change.